Co-Development Agreements

The National Cancer Institute's Technology Transfer Center (TTC) recognizes the importance of co-development in order to translate early-stage discoveries to outside entities to benefit public health. In support of this goal, the TTC establishes formal collaborative agreements with industry, academia, and non-profits to facilitate co-development through the exchange and development of research materials, knowledge, and technologies.

 

The TTC uses three different co-development agreements to help industry and academia interact and partner with National Institutes of Health laboratories and scientists to support technology development activities:

 

Agreements	Purpose	Essential Elements
Collaboration Agreement (CA)	Permits a two-way exchange of materials and information, and assumes exchange of results and/or conclusions will occur between NIH and companies, universities, state/local governments, Federal labs, and non-profits.	- Combines terms of a CDA and MTA - Simplified research plan - Exchange of new material created during the collaboration is  addressed - No funding from the outside party allowed - No license option - Rights to foreground IP are not addressed - Human and non-human materials covered
Cooperative Research and Development Agreement (CRADA)	Permits co-development of NIH or outside invention involving companies, universities, state/local governments, Federal labs, and non-profits.	For NIH: - May receive funds or in-kind contributions for collaborative research project - May provide confidentiality for research results up to five years after development    For Collaborator: - Option to exclusively license any inventions that are developed by a Federal laboratory employee(s) as part of the collaborative research     - Access to unique reagents and resources - Access to scientific and regulatory expertise - Access to Federal lab
Clinical Trial Agreement (CTA)	Transfers material into NIH for research in Human Subjects from companies, state/local governments, non-profits, universities	- Covers investigational data, drug, diagnostic, or device - No funding from the outside party required - No option to license foreground IP - Clinical and non-clinical - Addresses regulatory issues and monitoring - Addresses Personally Identifiable Information (PII)